Ionis Pharmaceuticals

Vico Therapeutics

Ionis axes eye disease from targets of Roche-partnered prospect after data disappoint

Fierce Biotech

Thu, 08/1/24 - 11:50 am

age-related macular degeneration

Roche

Ionis plots next steps for Angelman drug Biogen passed on

BioPharma Dive

Tue, 07/23/24 - 11:15 am

Angelman Syndrome

ION582

Ionis reveals an oasis for HAE patients as RNA med reduces attacks in phase 3

Fierce Biotech

Fri, 05/31/24 - 11:00 am

HAE

donidalorsen

European Commission grants marketing approval to Biogen's ALS drug

Reuters

Thu, 05/30/24 - 11:05 pm

Europe

Biogen walks away from Ionis-partnered ALS, Angelman prospects after peek at clinical data

ALS

Qalsody

Fierce Biotech

Thu, 05/16/24 - 11:38 am

ALS

Angelman Syndrome

5 Promising MASH Therapies That Could Follow Madrigal’s Rezdiffra

BioSpace

Mon, 04/15/24 - 11:24 am

MASH

NASH

Madrigal Pharmaceuticals

Rezdiffra

ACC: Ionis' rare metabolic disorder drug slides from 100% efficacy, but FDA ambitions unchanged

Fierce Biotech

Mon, 04/8/24 - 10:50 am

familial chylomicronemia syndrome

olezarsen

Ionis Pharma's fatty liver disease drug succeeds in mid-stage trial

Reuters

Wed, 03/13/24 - 10:43 am

Ionis says rare disease drug succeeds in late-stage HAE study

BioPharma Dive

Mon, 01/22/24 - 11:10 am

HAE

donidalorsen

FDA approves Ionis-AstraZeneca's nerve disease drug

Reuters

Fri, 12/22/23 - 09:42 am

Roche pays Ionis $60M upfront to license RNA-targeting Alzheimer's, Huntington's programs

Fierce Biotech

Wed, 09/27/23 - 10:14 am

Roche

RNA

Alzheimer's disease

Huntington's disease

Ionis Notches Phase III Win in Rare Genetic Disease, Plans to Submit NDA

BioSpace

Tue, 09/26/23 - 09:54 pm

Ionis' lipid-lowering drug hits phase 3 goal, raising hopes in untapped rare disease market

antisense

olezarsen

Fierce Biotech

Tue, 09/26/23 - 11:37 am

familial chylomicronemia syndrome

olezarsen

Spotlight – Nash in 2023 and beyond

EP Vantage

Thu, 08/3/23 - 10:03 am

AstraZeneca adds Latin America to Ionis ATTR partnership for $20M

Fierce Biotech

Fri, 07/28/23 - 11:48 am

AstraZeneca

Roche drops antisense drug after seeing efficacy data, leaving Biogen, Ionis and Ultragenyx to duke it out

Latin American

eplontersen

ATTR

Fierce Biotech

Fri, 06/23/23 - 09:46 am

Ultragenyx

rugonersen

FDA approves Biogen and Ionis’ Tofersen for rare genetic form of ALS

Medical Marketing and Media

Tue, 04/25/23 - 10:20 pm

Ionis, AstraZeneca's polyneuropathy med improved patients' quality of life in phase 3, teeing up battle with Alnylam

ALS

tofersen

FDA

Fierce Biotech

Mon, 04/24/23 - 10:26 am

Could This Rare-Disease Drug Candidate Become a Blockbuster?

Motley Fool

Wed, 04/19/23 - 10:26 am

AstraZeneca